Innate Pharma S.A. (EPA:IPH)
Market Cap | 156.06M |
Revenue (ttm) | 20.12M |
Net Income (ttm) | -49.47M |
Shares Out | 83.81M |
EPS (ttm) | -0.61 |
PE Ratio | n/a |
Forward PE | 1.39 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 53,498 |
Average Volume | 117,861 |
Open | 1.852 |
Previous Close | 1.876 |
Day's Range | 1.852 - 1.888 |
52-Week Range | 1.332 - 2.790 |
Beta | 0.86 |
RSI | 42.88 |
Earnings Date | Mar 27, 2025 |
About Innate Pharma
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an... [Read more]
Financial Performance
In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.
Financial StatementsNews

Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2024 financial results.

Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference.

Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Resp...
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Shares of Logility Supply Chain Solutions, Inc . (NASDAQ: LGTY) rose sharply in today's pre-market trading after Aptean announced an agreement to acquire Logility in a $14.30-per-share all-cash deal ...

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its P...

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York.

Innate Pharma Announces Transformative Strategy to Accelerate Growth
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its updated strategy for company growth. ...

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will present and host...

Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024
New data from Innate Pharma SA highlights quality-of-life improvements in patients with cutaneous T-cell lymphoma treated with lacutamab in the TELLOMAK...

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life...

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
MARSEILLE, France & DIAMOND BAR, Calif.--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), together with the Institute for Fo...

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab healt...

Innate Pharma: Looking Like A Company We'll Regret Ignoring
Innate has a stable of interesting pipeline projects in development for a range of cancers. The most advanced candidate is poised for a potential accelerated approval for cutaneous T-cell lymphoma. Ot...

Innate Pharma Releases Its 2025 Financial Calendar
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2025 financial calendar: March 27, 202...

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of ...
Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript
Innate Pharma reports 9M results
Innate Pharma S.A. 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Innate Pharma S.A.

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results...

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the ...

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for third quarter 2024 results and business updates.

Innate Pharma Announces Its Participation in Upcoming Investor Conferences
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences.